Navigation Links
Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant

The Anson Group is pleased to announce that Dr. Michael Langley is joining the company as a regulatory consultant after retiring from Eli Lilly & Co. Dr. Langley served many roles during his career with Lilly in both animal science and human pharmaceutical products, including director of regulatory affairs and clinical research. Dr. Langley led a number of successful regulatory engagements including both European and US regulatory submissions.

Indianapolis, IN (Vocus) January 30, 2010 -- The Anson Group announces today the addition of Dr. Michael Langley to its regulatory consulting practice. Dr. Langley is joining Anson Group after his recent retirement from Eli Lilly and Co. He has worked in the pharmaceutical industry since 1983, and has had a range of responsibilities and a broad variety of pharmaceutical products.

Early in his career, Dr. Langley worked for Elanco Animal Health, a Division of Eli Lilly, in a number of roles with increasing responsibilities including market research manager, project manager of animal health research, Director of European Regulatory and Clinical Affairs, and finally director of clinical research.

In 2002, Dr. Langley transitioned from animal health products to human pharmaceuticals at Eli Lilly. His experience includes establishing research priorities and timelines, successfully leading teams through US and EU marketing applications.

As the Director for Regulatory Affairs for Eli Lilly, Dr. Langley led project teams in label negotiations with the FDA, and several sNDA and sBLAapplications which resulted in approvals. Additionally, he has successfully guided several IND submissions, and also worked with FDA officials to remove a clinical hold placed on one molecule.    

“As we further expand the depth and breadth of our regulatory team, the addition of Dr. Langley’s oncology and CVM experience significantly contributes to our goal of providing the most experienced personnel needed to meet the exacting demands of every client project.” states Colleen Hittle, RAC, Managing Partner.

About Anson Group
Headquartered in Carmel Indiana, Anson Group is a minority-owned independent consulting organization with over 14 years experience as a leading provider of services and strategies for FDA product approval and compliance for devices, drugs, biologics, and combination products. Anson Group’s team of experienced industry experts tailors both enterprise strategies and clearly-defined action plans that help its clients address crucial issues throughout the product life cycle. Anson works with clients in the United States, Europe, and Asia, from global pharmaceutical manufacturers to small pre-IPO or VC biotechnology and medical device start-ups.


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
11. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
Post Your Comments:
Related Image:
Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant
(Date:12/1/2015)... Santa Clara, CA (PRWEB) , ... December 01, ... ... Atomic Force Microscopy (AFM) announces Park NX10 SICM Module, an add-on scanning ion ... that easily integratesthe power of SICM to an AFM. , Park SICM benefits ...
(Date:12/1/2015)... 2015 Dr. Harry Lander , President of Regen, ... Chief Science Officer and recruits five distinguished ... , President of Regen, expands his role to include ... five distinguished scientists to join advisory team --> ... role to include serving as Chief Science ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced ... new closed system for isolating adipose-derived stem cells. The announcement starts a new phase ... tissue. SVF is a component of the lipoaspirate obtained from liposuction of excess adipose ...
(Date:11/30/2015)... 2015 Partnership includes an MPP ... for the u niversity , s ... treatment s cale - up through ... Africa , where licensees based anywhere in the world will have ... --> Africa , where licensees based anywhere in the world ...
Breaking Biology Technology:
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... High Tech Association (MHTA) as one of only three ... the "Software – Small and Growing" category. The Tekne Awards ... who have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):